首页> 外文期刊>Anti-Cancer Drug Design >Sequence specificity and reactivity of the binding of phenazine-tethered platinum complexes to DNA.
【24h】

Sequence specificity and reactivity of the binding of phenazine-tethered platinum complexes to DNA.

机译:吩嗪系铂配合物与DNA结合的序列特异性和反应性。

获取原文
获取原文并翻译 | 示例
       

摘要

An in vitro transcription assay was used to probe the sequence specificity of the binding of phenazine-tethered platinum complexes to DNA. It was found that when compared to cis-dichloro(ethylenediamine)platinum(II), the number of RNA polymerase blockage sites was increased by approximately 50% and the blockage sites were broadened by 1-3 nucleotides by the presence of the phenazine ligand. The rate of platination was also enhanced by the presence of the intercalator, and the increase in the kinetics of platination resulted in increased levels of adducts formed (i.e. high drug occupancy) as detected under conditions of active transcription. The level of platination by derivative 3 was 20-fold greater than that of the reference compound, which lacked a tethered intercalating phenazine group.
机译:体外转录测定法用于探测吩嗪系铂复合物与DNA结合的序列特异性。已发现当与顺式二氯(亚乙基二胺)铂(II)相比时,由于吩嗪配体的存在,RNA聚合酶阻断位点的数目增加了约50%,并且阻断位点扩大了1-3个核苷酸。嵌入剂的存在也增加了镀铂的速率,并且在活性转录条件下检测到,镀铂动力学的增加导致形成的加合物的水平增加(即高药物占有率)。衍生物3的镀铂水平是参考化合物的20倍,而参考化合物没有栓系的吩嗪基。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号